| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/23/2001 | EP1101770A1 Derivatives of 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazole and 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazole, their process of preparation and pharmaceutical compositions containing them |
| 05/23/2001 | EP1101769A2 Nitrogen Containing Erythromycin Derivatives |
| 05/23/2001 | EP1101765A2 Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them |
| 05/23/2001 | EP1100964A1 Gene sequence variances with utility in determining the treatment of disease |
| 05/23/2001 | EP1100944A1 Targeted alphavirus and alphaviral vectors |
| 05/23/2001 | EP1100942A2 Herpes virus vectors for dendritic cells |
| 05/23/2001 | EP1100941A2 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
| 05/23/2001 | EP1100916A2 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100910A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100908A2 Human receptor-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100906A1 Kdel receptor inhibitors |
| 05/23/2001 | EP1100902A1 Keratinocyte derived interferon |
| 05/23/2001 | EP1100895A2 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100892A1 Use of prohibitin rna in treatment of cancer |
| 05/23/2001 | EP1100886A1 Tumor necrosis factor-gamma |
| 05/23/2001 | EP1100875A2 Inhibition of graft versus host disease |
| 05/23/2001 | EP1100873A1 Cancer cells from body fluids containing cells, isolation thereof and agents containing the same |
| 05/23/2001 | EP1100869A1 98 human secreted proteins |
| 05/23/2001 | EP1100830A2 Heterominibodies |
| 05/23/2001 | EP1100826A1 Isoforms of human calcium sensing receptor |
| 05/23/2001 | EP1100822A1 Secreted cysteine rich protein-6 (scrp-6) |
| 05/23/2001 | EP1100817A1 Endogenous retrovirus tumor associated nucleic acids and antigens |
| 05/23/2001 | EP1100814A2 Inhibitors of urokinase and blood vessel formation |
| 05/23/2001 | EP1100813A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |
| 05/23/2001 | EP1100808A1 Prostate derived ets factor |
| 05/23/2001 | EP1100807A1 STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| 05/23/2001 | EP1100804A1 Tin polyoxaalkanecarboxylates and compositions containing them |
| 05/23/2001 | EP1100802A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF |
| 05/23/2001 | EP1100801A2 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 05/23/2001 | EP1100792A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 05/23/2001 | EP1100788A1 Substituted quinazoline derivatives |
| 05/23/2001 | EP1100779A1 Substituted indolinones, the production thereof and their use as medicaments |
| 05/23/2001 | EP1100778A1 Oxidised sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents |
| 05/23/2001 | EP1100777A1 Sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents |
| 05/23/2001 | EP1100589A2 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| 05/23/2001 | EP1100548A2 Genetically engineered cells and tissues |
| 05/23/2001 | EP1100547A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 05/23/2001 | EP1100545A1 Regulated expression of recombinant proteins using rna viruses |
| 05/23/2001 | EP1100543A2 Conjugates targeted to the interleukin-2 receptors |
| 05/23/2001 | EP1100535A1 Targeting pharmaceutical agents to injured tissues |
| 05/23/2001 | EP1100532A2 Methods of using lanreotide, a somatostatin analogue |
| 05/23/2001 | EP1100528A2 Use of novel agents inducing cell death in synergy with interferons |
| 05/23/2001 | EP1100525A2 Modulation of apoptosis |
| 05/23/2001 | EP1100524A2 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 05/23/2001 | EP1100517A1 Nutrient and therapeutic compositions for the treatment of cancer |
| 05/23/2001 | EP1100515A1 $i(EX VIVO) TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS |
| 05/23/2001 | EP1100512A2 Preparation of thioarabinofuranosyl compounds and use thereof |
| 05/23/2001 | EP1100507A1 Antioxidant composition and method of treating diseases using same |
| 05/23/2001 | EP1100506A1 Integrin receptor antagonists |
| 05/23/2001 | EP1100493A1 INDOLE sPLA 2? INHIBITORS |
| 05/23/2001 | EP1100475A1 Use of drug-loaded nanoparticles for the treatment of cancers |
| 05/23/2001 | EP0722431B1 Oxidized carotenoids, retinoids and related conjugated polyenes, and derived fractions and compounds useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| 05/23/2001 | EP0689600B1 Process to induce the death of tumor cells |
| 05/23/2001 | EP0683784B1 7,42-bis (o-demethyl) rapamycin |
| 05/23/2001 | EP0669827B1 Compositions for the regulation of cytokine activity |
| 05/23/2001 | DE19956029A1 Active substance carrier system based on coating a substance with enzymatically cleavable side groups, useful for gene therapy especially of cancer and inflammation |
| 05/23/2001 | DE19955476A1 Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Bis-basic compounds as tryptase inhibitors, to processes for their preparation and their use as medicaments |
| 05/23/2001 | DE19943786A1 Antiviral agent, e.g. vaccine, antibody, agent that inhibits viral replication, transcription or translation, useful for preventing or treating tumors (or conditions which may become tumorous) associated with viral infections |
| 05/23/2001 | CN1296529A Method for screening therapeutic agents |
| 05/23/2001 | CN1296488A Bicycle hydroxamic acid derivatives |
| 05/23/2001 | CN1296481A (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 05/23/2001 | CN1296474A Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 05/23/2001 | CN1296416A Adjuvant compositions |
| 05/23/2001 | CN1296410A Methods for inhibiting MRP1 |
| 05/23/2001 | CN1296408A Methods for inhibiting MRP1 |
| 05/23/2001 | CN1296011A Purine L-nucleoside, its analogue and use thereof |
| 05/23/2001 | CN1296008A Dioxacyclopentedien-6-(5aH)-one compound, its preparation process and medicinal composition |
| 05/23/2001 | CN1295861A Presceiptions of nine moxa-perparations for moxibustion |
| 05/23/2001 | CN1295860A Traditional Chinese medicinal suppository fortreating rectal cancer |
| 05/23/2001 | CN1295854A External plaster for treating cancer and preparation process thereof |
| 05/23/2001 | CN1066151C Prodrugs of pacolitaxel derivatives |
| 05/23/2001 | CN1066150C Bridged indole as matrix metalloprotease inhibitors |
| 05/23/2001 | CN1066147C Purine derivatives and processes for their preparation |
| 05/23/2001 | CN1066142C 喹唑啉衍生物 Quinazoline derivatives |
| 05/23/2001 | CN1066057C Medicine for treating and proventing malignant tumors and preparation thereof |
| 05/23/2001 | CN1066049C Medicinal composition for treating digestive tract tumor |
| 05/22/2001 | US6235970 CICM cells and non-human mammalian embryos prepared by nuclear transfer of a proliferating differentiated cell or its nucleus |
| 05/22/2001 | US6235969 Cloning pigs using donor nuclei from non-quiescent differentiated cells |
| 05/22/2001 | US6235923 Retinoids and cell differentiation |
| 05/22/2001 | US6235907 Intermediates useful in making mappicine and related compounds |
| 05/22/2001 | US6235883 Human monoclonal antibodies to epidermal growth factor receptor |
| 05/22/2001 | US6235877 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 05/22/2001 | US6235791 Using cis n-cyclohexyl-n-ethyl(3-(3-chloro-cyclohexylphenyl)allyl)amine |
| 05/22/2001 | US6235782 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 05/22/2001 | US6235776 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| 05/22/2001 | US6235771 Anilide derivative, production and use thereof |
| 05/22/2001 | US6235768 Osteoporosis; rheumatic disorders; antitumor agents |
| 05/22/2001 | US6235764 Isothiazole derivatives useful as anticancer agents |
| 05/22/2001 | US6235756 Methods and compositions for inhibition of angiogenesis by thalidomide |
| 05/22/2001 | US6235750 Nitric oxide synthase inhibitor |
| 05/22/2001 | US6235727 Sulfonylaminophosphinic and sulfonylaminophosphinic acid derivatives, methods for their preparation and use |
| 05/22/2001 | US6235723 Antisense oligonucleotide modulation of human protein kinase C-δ expression |
| 05/22/2001 | US6235714 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 05/22/2001 | US6235712 Non-aqueous polar aprotic peptide formulations |
| 05/22/2001 | US6235525 Nucleotide sequence; diagnosis; vaccines; transfected cell line |
| 05/22/2001 | US6235523 Vector having nucleic acid encoding a human papillomavirus-16 e7 antigen lacking the rb protein binding site and operably linked to a cytomegalo virus promoter; vaccines |